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Abstract
Epigenetic modifications must underlie lineage-specific differentiation as terminally differentiated 
cells express tissue-specific genes, but their DNA sequence is unchanged. Hematopoiesis provides 
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a well-defined model to study epigenetic modifications during cell-fate decisions, as multipotent 
progenitors (MPPs) differentiate into progressively restricted myeloid or lymphoid progenitors. 
While DNA methylation is critical for myeloid versus lymphoid differentiation, as demonstrated 
by the myeloerythroid bias in Dnmt1 hypomorphs1, a comprehensive DNA methylation map of 
hematopoietic progenitors, or of any multipotent/oligopotent lineage, does not exist. Here we 
examined 4.6 million CpG sites throughout the genome for MPPs, common lymphoid progenitors 
(CLPs), common myeloid progenitors (CMPs), granulocyte/macrophage progenitors (GMPs), and 
thymocyte progenitors (DN1, DN2, DN3). Dramatic epigenetic plasticity accompanied both 
lymphoid and myeloid restriction. Myeloid commitment involved less global DNA methylation 
than lymphoid commitment, supported functionally by myeloid skewing of progenitors following 
treatment with a DNA methyltransferase inhibitor. Differential DNA methylation correlated with 
gene expression more strongly at CpG island shores than CpG islands. Many examples of genes 
and pathways not previously known to be involved in choice between lymphoid/myeloid 
differentiation have been identified, such as Arl4c and Jdp2. Several transcription factors, 
including Meis1, were methylated and silenced during differentiation, suggesting a role in 
maintaining an undifferentiated state. Additionally, epigenetic modification of modifiers of the 
epigenome appears to be important in hematopoietic differentiation. Our results directly 
demonstrate that modulation of DNA methylation occurs during lineage-specific differentiation 
and defines a comprehensive map of the methylation and transcriptional changes that accompany 
myeloid versus lymphoid fate decisions.
Hematopoietic stem cells (HSC) can self renew for life and differentiate into all myeloid and 
lymphoid blood lineages2 (Fig. 1a). Recent evidence suggests that DNA methylation plays a 
direct role in regulating both HSC self-renewal and commitment to lymphoid versus 
myeloid fates1,3. Although the frequencies of myeloid progenitors and differentiated cells 
were normal in Dnmt1-hypomorphic mice, lymphoid-restricted CLPs and their downstream 
thymic T cell progenitors (DN1, DN2 and DN3) were diminished. In the bone marrow of 
Dnmt1-hypomorphs, lymphoid, but not myeloid, transcripts were reduced, and promoters of 
two myeloerythroid genes were hypomethylated in HSCs. These observations support a 
critical role for DNA methylation in lymphocyte development, possibly through regulation 
of gene expression.
Here we have examined genome-wide methylation profiles of the mouse hematopoietic 
system, because it provides the first opportunity to examine differential methylation of a 
hierarchical progression of purified cell populations with well-characterized differentiation 
potentials (Fig. 1a). Eight populations, ranging from uncommitted MPP through oligopotent 
progenitors specified during myeloid versus lymphoid fate decisions, were FACS-purified 
and subjected to Comprehensive High-throughput Array-based Relative Methylation 
(CHARM) analysis (Fig. 1a and Supplementary Fig. 1). This approach investigated the 
methylation status of CpGs throughout the mouse genome using an algorithm favoring 
regions of higher CpG density (including all CpG islands4), but without bias for CpG 
location relative to genes5. Using CHARM, we recently found that differential methylation 
occurs more frequently in CpG island “shores” (regions within 2kb of an islands) than in 
CpG islands during multiple cellular differentiation processes6,7. Additionally, mRNA of 
each population was subjected to microarray and RT-PCR analyses to generate gene 
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expression data. Thus, we were able to directly compare differentially methylated regions 
(DMRs) throughout the genome with expression levels of nearby genes for all eight 
populations.
This analysis revealed DMRs in numerous genes known to play a role in lymphoid or 
myeloid fate specification. For example, Lck, the src family kinase member responsible for 
initiating signaling downstream of the T cell receptor (TCR)8, was transcriptionally 
upregulated from DN1 to DN3, consistent with its role in pre-TCR signal transduction (Fig. 
1b). Interestingly, as Lck transcription was upregulated, CpGs in exon 1 through intron 2 
were progressively demethylated (Fig. 1b). Similarly, myeloid specification from MPP 
through GMP was accompanied by transcriptional upregulation and progressive 
hypomethylation of Mpo, which encodes an enzyme central to the microbicidal activity of 
neutrophils9 (Fig. 1c). Additionally, Cxcr2, which encodes a chemokine receptor 
responsible for neutrophil chemotaxis10, was upregulated during myeloid commitment from 
CMP through GMP, while the gene was demethylated (Supplementary Fig. 2a). 
Furthermore, Gadd45α, which is implicated in myeloid development11, was found to be 
concomitantly upregulated and demethylated in the CMP to GMP transition (Supplementary 
Fig. 2b). Gadd45α can actively demethylate DNA in different model systems12,13; thus, 
hypomethylation of Gadd45α during myelopoiesis may promote further hypomethylation of 
genes regulating myeloid commitment; however, the role of Gadd45α in promoting 
demethylation is still controversial14. Taken together, these data indicate that CHARM 
analysis correctly identifies DMRs in known lymphoid and myeloid specifying genes, each 
confirmed by pyrosequencing and gene expression analysis, making it a valuable tool for 
identifying candidate genes important for lymphoid or myeloid fate specification.
Viewed globally, CHARM analysis revealed striking epigenetic plasticity, resulting in 
increased overall methylation upon lymphoid relative to myeloid commitment (Table 1). 
Most DMRs distinguishing MPPFL+ cells from CLP lost methylation during this step of 
early lymphoid commitment, but upon the subsequent transition to DN1, 15-fold more 
DMRs showed gain, as opposed to loss, of methylation. Similarly in the earliest step of 
myeloid commitment from MPPFL+ to CMP there were substantially more hypermethylated 
than hypomethylated DMRs, but nearly all DMRs showed loss of methylation on transition 
from CMP to GMP. Comparing DN1 to GMP, two populations similarly differentiated 
towards lymphoid and myeloid fates, respectively, there were 8-fold more DMRs with 
higher-level methylation in DN1 cells, suggesting a skewing toward greater methylation in 
lymphoid compared to myeloid hematopoiesis. These observations might explain why 
Dnmt1-hypomorphic mice, which are unable to properly maintain CpG methylation, have 
normal myeloid, but diminished lymphoid development1,3.
To test the hypothesis that reduced methylation preferentially promotes myeloid as opposed 
to lymphoid differentiation, we turned to an in vitro assay system that promotes both 
myeloid and lymphoid development15,16. In the presence of 5-aza-2′-deoxycytidine, the 
percentage of myeloid progeny increased at the expense of lymphoid progeny for MPPFL+, 
CLP, DN1 and DN2, but not DN3, which remained lymphoid committed (Supplementary 
Fig. 3a–b). This myeloid skewing was most pronounced in DN1 cells, perhaps indicating 
that the large number of methylated DMRs in DN1 compared to CLP is critical for lymphoid 
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specification (Table 1). We conclude that inhibiting DNA methylation promotes myeloid 
versus lymphoid specification, providing a mechanism for the myeloid skewing observed in 
Dnmt1 hypomorphs1.
Consistent with our previous studies6,7, most DMRs were in CpG island shores (Table 1). 
The exceptions were for MPPFL− vs. MPPFL+, and MPPFL+ vs. CLP, in which most DMRs 
were in CpG islands: interestingly, both of these transitions are involved in early 
differentiation. Differential DNA methylation and gene expression showed a statistically 
significant inverse relationship particularly at CpG island shores (Fig. 2 and Supplementary 
Fig. 4). As the CHARM array design was targeted toward CpG density but not gene 
architecture per se, we also created a new array that included all promoters, and hybridized 
DNA from three of the groups studied earlier. Analysis showed a similar statistically 
significant inverse relationship between differential DNA methylation and gene expression, 
again particularly at CpG island shores (Supplementary Fig. 4g–h). Thus, CpG island shores 
are the regions with the most variability in DNA methylation between hematopoietic 
populations, and this variability correlates best with changes in gene expression. [However, 
not all DNA methylation changes correlated with changes in gene expression: for example, 
Tha1 is demethylated during lymphoid specification (see CHARM plots on http://
charm.jhmi.edu/hsc), but is expressed at high levels from MPP through DN3. In converse, 
and as expected since there are multiple mechanisms for epigenetic regulation, we also 
identified lineage-specifying genes with changes in expression levels, but not in DNA 
methylation, such as Gata3 and Hes1 (see microarrays deposited in GEO).
Many novel genes with the potential to contribute to myeloid/lymphoid fate specification 
were revealed by comparing CHARM-identified DMRs with gene expression data. For 
example, Arl4c, a member of the ADP-ribosylation factor family of GTP-binding proteins, 
was upregulated and hypomethylated in DN1-3 thymocytes (Fig. 3a). Arl4c may play a role 
in vesicular transport17, but its role in lymphoid specification is unknown. Multiple other 
genes with DMRs suggestive of a role in lymphoid development, such as Smad7, Gcnt2 and 
Cited2, were also identified (Supplementary Fig. 5). Smad7, which negatively regulates 
TGF-beta signaling, is selectively upregulated and hypomethylated at the earliest stages of 
thymocyte development, suggesting a role in promoting lymphopoiesis (Supplementary Fig. 
5a). However, it causes myeloid lineage skewing when overexpressed in human cord blood 
progenitors18. Gcnt2 transcripts were downregulated in thymocyte progenitors, and the 
locus became hypermethylated progressively in DN1-3 progenitors (Supplementary Fig. 5b), 
consistent with a role for Gcnt2 in enabling the myeloid potential that is lost during final 
lymphoid lineage commitment at the DN3 stage19,20.
Novel potential regulators of myelopoiesis were also identified. The Jdp2 locus was 
hypomethylated and its transcript was upregulated in CMP and GMP relative to thymocyte 
progenitors (Fig. 3b). Jdp2 is thought to repress transcription by recruiting histone 
deacetylases and regulating nucleosome assembly21. Dach1 was also hypomethylated and 
expressed from MPPFL− through GMP, but was silenced in CLP and DN1-3 thymocyte 
progenitors (Supplementary Fig. 5d), suggesting it may contribute to myelopoiesis. Dach1 
has been implicated in transcriptional repression through association with histone 
deacetylases and its drosophila homolog is known to play a role in gonadal, limb, and ocular 
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development22. Thus, Jdp2 and Dach1 may feedback on the epigenome to control 
expression of tissue specific genes, but their role in hematopoiesis remains uncharacterized.
Our analyses also revealed a set of genes that were progressively hypermethylated and 
transcriptionally silenced as differentiation progressed towards both myeloid and lymphoid 
fates, suggesting a role in maintenance of a multipotent state. Meis1, 2900052L18Rik, Hlf, 
Hoxa9 and Prdm16 are all such candidates (Fig. 3c and Supplementary Fig. 6). Meis1 is 
known to be required for hematopoiesis and megakaryocyte lineage development23 and may 
function cooperatively with Hoxa9 to regulate hematopoiesis24. Furthermore, both Hlf and 
Prdm16 have been implicated in hematopoiesis25,26.
Lastly, epigenetic chromatin modifiers, including Hdac7a and Dnmt3b, were also 
differentially methylated during hematopoietic differentiation, suggesting feed-forward 
mechanisms that could expand and lock in epigenetic programming necessary for cell fate 
commitment (Fig. 3d and Supplementary Figure 7). Hdac7, which encodes a histone 
deacetylase and represses transcription, was demethylated and upregulated in DN1-DN3 
thymocytes (Fig. 3d). Since Hdac7 is highly expressed in DN3 cells, which can no longer be 
reprogrammed toward a myeloid fate by ectopic IL-2R signaling19, it may actively repress 
genes responsible for maintaining myeloid lineage potential19. In contrast, Dnmt3b, a 
methyltransferase responsible for de novo CpG methylation, is hypermethylated and 
downregulated progressively in CMPs and GMPs (Supplementary Figure 7). Dnmt3a and 
Dnmt3b were shown to be essential for HSC self-renewal, but their roles in lineage 
commitment remain inconclusive27. Downregulation of Dnmt3b in myeloid committed cells 
could prevent new DNA methylation, helping to maintain the observed hypomethylated 
state associated with myelopoiesis. In addition, the upregulation of Dnmt3b in DN1 
independent of DNA methylation changes might explain the dramatic acquisition of DNA 
methylation from CLP to DN1 (Table 1).
In summary, these data provide a comprehensive map of the methylome during myeloid and 
lymphoid commitment from hematopoietic progenitors. To facilitate the general 
accessibility of the methylome for these hematopoietic progenitors, we also provide here a 
novel web platform with which the methylation status of any genomic locus of interest can 
be easily queried to generate output methylation plots. In addition to identifying candidate 
genes for further investigation, the data suggest several important themes for the epigenetics 
of lineage-specific differentiation. First, myelopoiesis and lymphopoiesis achieve markedly 
different methylation endpoints in differentiation, with lymphopoiesis depending much more 
heavily on the acquisition of DNA methylation marks, and myelopoiesis depending much 
more on their loss. Besides providing a mechanism for the proposed DNMT1-dependence of 
lymphopoiesis, these results may also explain the therapeutic specificity of DNA 
demethylating drug treatment of myelodysplasia, in which malignant cells arrested in early 
development may be induced to differentiate by DNA demethylation28. In addition, the 
results show a remarkable dynamic plasticity in methylation during lineage development. 
The changes are evocative of Waddington’s illustrations of hills and valleys in the 
epigenetic landscape of development. We have recently proposed that development depends 
on dynamic stochastic variation in the epigenetic landscape in a given genetic 
environment29, and the maturation of undifferentiated progenitors to progressively more 
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differentiated states could restrict that variation. Support for this idea is provided in an 
accompanying manuscript in this journal examining the epigenetic memory in iPS cells 
derived from fibroblasts and blood30. In that paper, lymphocyte-derived iPS cells cluster 
with CLP but not the myeloid lineage using DNA methylation differences we identified, 
suggesting the existence of lymphocyte memory in these iPS cells consistent with the DNA 
methylation profiles described in this paper.
Methods Summary
Flow cytometry
Bone marrow cells and thymocytes were stained with monoclonal antibodies, then analyzed 
and sorted using a FACSAria. Antibody details are provided in Online Methods.
CHARM DNA methylation analysis
Genomic DNA was isolated from samples, fractionated, digested, purified, labeled and 
subject to CHARM array analysis as previously described7. Details are provided in Online 
Methods.
Bisulfite pyrosequencing
Genomic DNA was isolated from cells, treated with bisulfite and amplified by PCR. DNA 
methylation was measured by quantitative pyrosequencing. Details are provided in Online 
Methods.
Affymetrix microarray expression analysis
Genome-wide gene expression analysis was performed using the Affymetrix GeneChip 
Mouse Genome 430 2.0 Array. Details are provided in Online Methods.
OP9:OP9DL1 stromal co-cultures
50 double sorted progenitors were cultured in wells containing confluent 1:1 OP9:OP9DL1 
stromal cells in the presence of cytokines. At day 6, the cells in each well were stained and 
analyzed by flow cytometry. Details are provided in Online Methods.
Quantitative PCR
Cells were sorted into TRIzol, RNA was isolated and cDNA was synthesized. Real-time 
PCR was performed using SYBR Green reagents. Details are provided in Online Methods.
DNA methylation query website
DNA methylation in any region from the CHARM array can be plotted at http://
charm.jhmi.edu/hsc. Details are provided in Online Methods.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Examples of known lineage-related genes showing differential DNA methylation 
between lymphoid and myeloid progenitors
a, Hematopoietic progenitors included in this study. Dashed-arrow indicates existence of 
intermediate progenitors. DMR in b, Lck and c, Mpo. Upper panels: top half: CpG 
methylation (p); lower half: CpG dinucleotides (black tick marks), CpG density (curve), 
CpG islands (orange lines) and the gene annotation (see online Methods). Middle panels: 
methylation of individual CpGs (in the red boxes), mean values connected by lines. Bottom 
panels: mRNA expression levels, normalized to the highest expression among the 
populations (mean ± s.d., n=3; 5 for MPPFL− for microarrays).
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Figure 2. Gene expression correlates strongly with DMRs at shores
DMRs within 2kb of gene TSSs (black circles) were divided into two groups: Island (inside, 
cover, or overlap more than 50% of a CpG island), and Shores (up to 2000bp away from a 
CpG island). After RMA preprocessing, the log2 ratios of the gene expression differences 
(from leftto right) were plotted against Δp (left group minus right group). Black pluses 
represent random DMR-gene pairs more than 2kb apart. Wilcoxon rank-sum tests were 
performed to test the null hypothesis. a, MPPFL− vs. DN3_DMRs. b, MPPFL− vs. 
GMP_DMRs.
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Figure 3. CHARM identified genes with previously unknown functions in lymphoid/myeloid 
lineage commitment and pluripotency maintenance
a and b, Examples of DMRs with methylation changes in lymphoid/myeloid progenitors. a, 
the DMR in Arl4c. b, the DMR in Jdp2. C, the DMR in Meis1. D, the DMR in Hdac7a. The 
CHARM plots, pyrosequencing, Affymetrix GeneChip, and RT-PCR data are organized and 
displayed as in Fig. 1b.
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